BioRestorative Therapies (BRTX) Stock Price, News & Analysis

Company Overview

BioRestorative Therapies, Inc. is a clinical-stage regenerative medicine company based in Fort Lauderdale, Florida, focused on advancing stem cell-based therapies to address unmet medical needs. Established in 2005, the company leverages a proprietary platform of adipose‐derived mesenchymal stem cells (MSCs) to develop treatments with potential immunomodulatory and anti‐inflammatory properties. BioRestorative’s research and development activities encompass preclinical and clinical programs designed to harness the regenerative capacity of MSCs for a range of serious conditions.

The company’s lead program, ORBCEL‐C, targets steroid‐refractory acute graft‐versus‐host disease (GvHD) in pediatric patients. ORBCEL‐C has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration, reflecting the program’s potential to offer a novel approach where existing therapies have limited efficacy. BioRestorative has also advanced Brio™‐RK, an investigational treatment for dry eye disease, through a pivotal clinical trial pathway, aiming to provide a single‐dose, cell‐based solution that addresses underlying pathology rather than only symptoms.

Beyond its lead assets, the company maintains a diverse pipeline that includes ORBCEL‐M for potential use in multiple sclerosis and additional early‐stage projects exploring MSC applications in ulcerative colitis and neurological disorders. BioRestorative collaborates with contract development and manufacturing organizations to produce clinical‐grade MSCs under Good Manufacturing Practice (GMP) conditions. These partnerships support scalable production and quality control as programs advance toward pivotal trials and potential commercialization.

BioRestorative serves the U.S. market while evaluating global expansion opportunities through strategic alliances. The company is led by President and CEO William Foley and a management team with extensive experience in biotechnology research, clinical development, and regulatory affairs. With a commitment to scientific rigor and patient impact, BioRestorative Therapies continues to pursue innovative stem cell therapies aimed at transforming treatment paradigms for challenging diseases.

Key Stats

• Today's Range: $1.59 to $1.68
• 50-Day Range: $1.52 to $2.00
• 52-Week Range: $1.21 to $2.55
• Volume: 17,993 shs
• Average Volume: 238,897 shs
• Market Capitalization: $12.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed this year?

BioRestorative Therapies' stock was trading at $1.43 at the beginning of 2025. Since then, BRTX shares have increased by 13.3% and is now trading at $1.62.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies shares reverse split before market open on Wednesday, October 27th 2021.The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioRestorative Therapies investors own include Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), Onconova Therapeutics (ONTX) and American Graphite Technologies (AGIN).

Company Calendar

• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Healthcare
• Current Symbol: OTCMKTS:BRTX
• CIK: 1505497
• Web: www.biorestorative.com
• Phone: (631) 760-8100
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.50 million
• Net Margins: -13,728.83%
• Pretax Margin: -13,728.83%
• Return on Equity: -120.47%
• Return on Assets: -114.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.81
• Quick Ratio: 14.81

Sales & Book Value

• Annual Sales: $391 thousand
• Price / Sales: 31.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.65 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 7,505,000
• Free Float: 3,660,000
• Market Cap: $12.16 million
• Optionable: Not Optionable
• Beta: 75.28